AFT - Chief Financial Officer update

Tuesday 24th March 2026

AFT Pharmaceuticals (NZX: AFT ; ASX: AFP), New Zealand’s largest domestic pharmaceuticals company, today advises Chief Financial Officer-designate Simon Bosley has decided not to take up the role for personal reasons.

Simon has, however, committed to remain with the company until the end of July, while it recruits a new Chief Financial Officer to replace Malcolm Tubby, who is to retire at the end of May 2026.

AFT Managing Director Dr Hartley Atkinson thanked Simon for his engagement and his support during the transition period.

Released for and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial Officer.

For more information:

Investors Media

Dr Hartley Atkinson Richard Inder

Managing Director The Project

AFT Pharmaceuticals Tel: +64 21 645 643

Tel: +64 9488 0232

About AFT Pharmaceuticals

AFT is a growing New Zealand based multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription, and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs. Our business model is to develop and in-license products for in our markets of Australia, New Zealand, Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland, and UK, and to out-license our products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit our website www.aftpharm.com.

Chief Financial Officer update

Comments from our readers

No comments yet